The Technical Analyst
Merck & Co Inc [MRK]
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers—General
Merck & Co Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.64% $129.55
America/New_York / 8 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 328 126 mill |
| EPS: | 0.900 |
| P/E: | 143.94 |
| Earnings Date: | Jul 30, 2024 |
| SharesOutstanding: | 2 532.81 mill |
| Avg Daily Volume: | 8.21 mill |
| RATING 2024-05-08 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 9.33x |
| Company: PE 143.94 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 5.97x |
| Company: PE 143.94 | industry: PE 24.13 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$123.57 (-4.62%) $-5.98 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 127.55 - 131.55 ( +/- 1.54%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-05-04 | Smart Dalton | Buy | 612 | Common Stock |
| 2024-05-03 | Smart Dalton | Buy | 1 530 | Common Stock |
| 2024-05-04 | Smart Dalton | Sell | 302 | Common Stock |
| 2024-05-03 | Smart Dalton | Sell | 590 | Common Stock |
| 2024-05-03 | Smart Dalton | Buy | 516 | Common Stock |
| INSIDER POWER |
|---|
| 25.86 |
| Last 99 transactions |
| Buy: 1 325 861 | Sell: 852 034 |
Forecast:
16:00 - $129.48
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $129.48
Forecast 2: 16:00 - $129.48
Forecast 3: 16:00 - $129.48
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $129.55 (-0.64% ) |
| Volume | 6.60 mill |
| Avg. Vol. | 8.21 mill |
| % of Avg. Vol | 80.37 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MRK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest Press Releases
2024-05-08 06:45:00 - Press Release
Merck To Participate In The Bank Of America Securities 2024 Healthcare Conference
Rahway, n.j.--(business wire)---- $mrk #mrk--merck to participate in the bank of america securities 2024 healthcare conference.
2024-05-06 01:00:00 - Press Release
Press Release Biocartis Nv: Biocartis And Merck To Collaborate On Improving Patient Access To Personalized Medicine In Middle East And North Africa (mea) Region
Press release - 06/05/2024, 07:00 cest biocartis and merck to collaborate on improving patient access to personalized medicine in middle east and north africa (mea) region biocartis (mechelen, belgium) announced an expansion of its collaboration with merck serono middle east and merck saudi ltd., both affiliates of merck kgaa (“merck”).
2024-05-01 07:15:00 - Press Release
Merck Announces Phase 3 Keynote-811 Trial Met Dual Primary Endpoint Of Overall Survival (os) As First-line Treatment In Patients With Her2-positive Advanced Gastric Or Gastroesophageal Junction (gej) Adenocarcinoma
Rahway, n.j.--(business wire)---- $mrk #mrk--merck announces keynote-811 trial met dual primary endpoint as first-line treatment in patients with her2-positive advanced gastric or gej cancer.
2024-04-29 09:00:00 - Press Release
Merck Announces Positive Data For V116, An Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed For Adults
Rahway, n.j.--(business wire)---- $mrk #mrk--merck announces positive data for v116, an investigational, 21-valent pneumococcal conjugate vaccine specifically designed for adults.
2024-04-25 06:30:00 - Press Release
Merck Announces First-quarter 2024 Financial Results
Rahway, n.j.--(business wire)---- $mrk #mrk--merck announces first-quarter 2024 financial results.
Latest News
2024-05-03 10:56:22 - Zacks Investment Research
Here's Why Merck (MRK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
2024-04-25 14:40:58 - Schaeffers Research
Dow Earnings: How Merck, Caterpillar Shares Are Faring
Dow Jones Industrial Average (DJI) components Caterpillar Inc. (NYSE:CAT) and Merck & Co Inc (NYSE:MRK) are moving in opposite directions today after their respective first-quarter earnings reports, as the blue-chip index eyes its worst single-day decline since March 2023.
2024-04-25 13:11:23 - Zacks Investment Research
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024.
2024-04-25 11:36:05 - Investopedia
Merck's Cancer Drug and Vaccine Sales Drive Better-Than-Expected Results
Merck (MRK) shares advanced in intraday trading Thursday after the pharmaceutical firm reported better-than-expected quarterly results, and raised and narrowed its guidance on strong sales of its blockbuster cancer-fighting treatments.
2024-04-25 11:31:05 - Zacks Investment Research
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2024-04-25 09:51:12 - Proactive Investors
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda helped it post a profit and sales beat. Revenues during the group's first quarter reached US$15.78 billion, topping analysts' expectations of US$15.2 billion.
2024-04-25 06:33:23 - Reuters
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil.
2024-04-25 06:32:28 - CNBC
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.
2024-04-25 06:31:00 - Market Watch
Merck's first-quarter results beat expectations amid healthy vaccine-sales growth
Merck & Co. Inc. on Thursday reported first-quarter results that beat analysts' expectations amid strong sales of vaccines and cancer drug Keytruda.
2024-04-24 13:06:03 - Zacks Investment Research
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.